ページ2 - 最高の甲状腺機能検査医師 - トップ88名の医師

ユニヴァーシティ・プロフェッサー ドクター アントン・ルガーは、オーストリアにおける 内分泌学、糖尿病学、代謝疾患の第一人者であり、内科医学での画期的な研究とリーダーシップで広く認識されています。彼の数十年にわたるキャリアは、オーストリアおよび国際的な臨床実践と学術医学の双方に影響を与えてきました。

彼はウィーン大学で医学を学び、1970年代に学位を取得、その後ウィーン総合病院（AKH）で 内科医学および内分泌学を専門としました。ホルモンおよび代謝調節に対する彼の初期の興味は、糖尿病、下垂体および甲状腺疾患、そして神経内分泌腫瘍の研究に彼を導きました。

      1970年代 – ウィーン大学での医学研究を修了し、内科医学のレジデンシーを開始しました。

      1980年代 – 内分泌学および糖尿病学を専門とし、ホルモン調節と代謝研究に焦点を当てました。

      1990年代 – ウィーン医科大学にて 内分泌代謝学部の教授および部長に任命され、ヨーロッパで最も進んだホルモン障害センターの一つを率いています。

      2000年代–2010年代 – 糖尿病管理、下垂体および副腎疾患、および革新的なホルモン療法について幅広く出版し、多数の国際臨床試験に貢献しました。

     現在 – ウィーナー私立クリニックの上級顧問として勤務し、研究、教育、若手医師の指導に積極的に関与しています。

ルガー教授の臨床専門は、糖尿病、甲状腺および下垂体疾患、肥満、骨粗鬆症に加え、稀な内分泌シンドロームにも及びます。彼の業績は、オーストリアにおける現代のホルモン療法および糖尿病管理の発展に大きな影響を与えました。

学問的な卓越性と患者中心のケアへの献身で知られるルガー教授は、科学的な精密さと深い共感を兼ね備え、最新の医学知識に基づいた個別のアプローチを患者一人ひとりに確実に提供しています。彼の貢献は、ヨーロッパの指導的な内分泌学者の一人として国際的に認められています。

Anyarat Vichayawannakul, M.D.

Expertise

INTERNAL MEDICINE / ENDOCRINOLOGIST AND METABOLISM 

Graduation (M.D. From)

Bachelor of Medicine, Faculty of Medicine, Chulalongkorn University (Second Class Honor)

Certificates

Diploma in Internal Medicine, Faculty of Medicine, Chulalongkorn University

Diploma in Endocrinology and Metabolism, Rajavithi Hospital, Department of Medical Services .

Current Positions

INTERNAL MEDICINE / ENDOCRINOLOGIST AND METABOLISM AT INTRARAT HOSPITAL

Dr. Saban Sec is a medical oncologist with experience at leading hospitals, including Haseki Training and Research Hospital, Prof. Dr. Cemil Taşcıoğlu City Hospital, and Bahçelievler Medikalpark Hospital. He currently represents specialist physicians in the Turkish Medical Oncology Association. He is also a member of the Istanbul Medical Chamber and the Turkish Medical Oncology Association.

Dr. Sec treats breast, lung, gastrointestinal, prostate, urogenital, head and neck cancers, as well as sarcomas and rare tumors. He has published many peer-reviewed articles on cancer prognosis, treatment outcomes, and survival rates. His research includes studies with large patient groups, such as 138 patients with HER2-positive metastatic gastric cancer. Dr. Sec focuses on prognostic factors and treatment responses in different cancers. He is dedicated to improving cancer care.

Univ. Prof. Dr. Philipp Rissは、オーストリアの代表的な内分泌および一般外科医で、甲状腺、副甲状腺、および副腎の手術における専門性および内分泌腫瘍学に関する研究で国際的に認識されています。彼の正確な外科技術とエビデンスに基づいたアプローチは、彼をオーストリアの内分泌および代謝外科の最も尊敬される権威の一人にしました。

彼はウィーン大学で医学を学び、1990年代に卒業し、ウィーン医科大学で一般および臓器外科のレジデントを終えました。キャリアの初期において、彼は内分泌障害の外科的治療に特化し、代謝およびホルモン調節の知識を高度な低侵襲手術技術と組み合わせました。

     1990年代 – ウィーン大学での医学研究と外科訓練を完了。

     2000年代 – 内分泌および代謝外科を専門とし、甲状腺摘出術、副甲状腺切除術、および副腎手術を実施。

     2010年代 – ウィーン医科大学の外科准教授に任命され、甲状腺がん、副甲状腺機能亢進症、内分泌腫瘍管理に関する研究を進める。

     今日 – ウィーン私立クリニックおよびウィーン総合病院（AKH）でシニアコンサルタントとして勤務し、内分泌腫瘍学、ホルモン関連疾患、精密外科療法に注力。

Prof. Rissは、甲状腺および副甲状腺障害、内分泌腫瘍の生物学、術後の結果に関して広範で出版しており、内分泌外科における現在のヨーロッパ標準の形成に貢献しています。また、学術教育および国際外科協力に深く関与し、次世代の内分泌外科医を指導しています。

正確な技術、科学的厳格さ、そして患者への共感で知られるProf. Rissは、内分泌および代謝外科における最高レベルの卓越性を象徴しており、精密さとケアが長期的な結果を決定します。

Education and Expertise

(1994 – 2000) - GATA Faculty of Medicine Ankara

(2003 – 2007) - GATA Medical Faculty Pediatrics and Diseases

(2008 -2011) - Ankara University Pediatric Endocrinology

(03.03.2014) - Associate Professorship, Pediatric Endocrinology

(17.07.2019) - Professorship, Istinye University Faculty of Medicine

Experience

(2001 – 2003) - Special Forces Command/Ankara

(2007 – 2008) - Etimesgut Military Hospital/Ankara

(2011 – 2013) - GATA Medical Faculty Hospital/Ankara

(2013-2015) - GATA Haydarpasa Training Hospital/Istanbul

(05.2015-09.10.2017) - May 2015-09.10.2017 - Süleymaniye Gynecology and Pediatrics Training and Research Hospital/Istanbul

(07.2015 – 01.2016) - Suleymaniye Gynecology and Pediatrics Training and Research Hospital Pediatrics Administrative Responsibility/Istanbul

01.2016 - 09.11.2017 - Suleymaniye Gynecology and Pediatrics Training and Research Hospital Pediatric Clinic Education Responsibility / Istanbul

(03.03.2016 - 30.10.2017) - Süleymaniye Gynecology and Pediatrics Training and Research Hospital Management

(2017-2020) - Istinye University Faculty of Medicine Faculty Member

(2020-Present) - Istanbul Aydın University Faculty of Medicine Faculty Member

(20.10.2020-Present) - Head of Department of Child Health and Diseases, Faculty of Medicine, Istanbul Aydın University

Courses and Certificates

2001 - Flight Doctor Course

2010 - Project Management Training Course

2013 - Basic Epidemiology course

2018 - Trainer Training Course

Professional Memberships

Pediatric Endocrinology and Diabetes Association

European Society of Pediatric Endocrinology (ESPE)

Istanbul Medical Chamber

Awards

İhsan Turan, Ian Hutchins, Bülent Hacıhamdioğlu, Leman Damla Kotan, Fatih Gürbüz, Mehmet Taştan, Ayça Ulubay, Eda Mengen, Bilgin Yüksel, Susan Wray, Ali Kemal Topaloğlu. CCDC141 Mutation in idiopathic hypogonadotropic hypogonadism. XVI. First Prize in Oral Presentation at the National Pediatric Endocrine and Diabetes Congress.

Bülent Hacıhamdioğlu, Gönül Öçal, Merih Berberoğlu, ZeynepŞıklar, Ercan Tutar, Suat Fitöz, Gökhan Nergizoğlu, Şenay Savaş Erdeve, Emine Çamtosun. Control of premature microvascular aging and cardiovascular performance in obese adolescents. XVI. was held in Samsun on 6-10 November 2012. Second Prize in Oral Presentation at the National Pediatric Endocrine and Diabetes Congress.

Z. Siklar, G. Ocal, M. Berberoglu, B. Hacıhamdioğlu, Ş. Savas Erdeve, Y. Egin, N. Akar. Control of hypercoagulability caused by obesity in children with endothelial microparticle level and thrombin generation test, and the relationship between risk and metabolic parameters. First Prize in Oral Presentation at the 55th Turkish National Pediatrics Congress held in Antalya on 12-16 October 2011

Z. Şıklar, V. Topçu, P. Kocaay, M. Berberoğlu, B. Hacıhamdioğlu, S.S. Erdeve, H.R. Ilgin, A. Tükün, G. Öcal. Clinical Characteristics of Our Cases with Mutation in the Androgen Receptor Gene. XVI. was held in Samsun on 6-10 November 2012. First Prize in Oral Presentation at the National Pediatric Endocrine and Diabetes Congress.

Associate Professor Dr. Yusuf AÇIKGÖZ
Specialization: Medical Oncology

Education:

• 2004-2011: İnönü University Faculty of Medicine
• 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
• 2017-2022: Health Sciences University, Medical Oncology

Professional Experience:

• 2016-2017: Bingöl City Hospital, Internal Medicine
• 2021-2022: Health Sciences University, Medical Oncology
• 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
• 2023-2024: Ohio State University, Medical Oncology
• 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

Clinical Trials, Courses, Certifications:

Clinical Trials:

• 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
• 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

Courses:

• 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
• 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
• 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
• 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
• 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

Certifications:

• Ongoing: ECFMG Certification
• 2024: CITI Responsible Conduct of Research (The Ohio State University)
• 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
• 2024: CITI Human Subjects Protection (The Ohio State University)
• 2024: CITI Good Clinical Practice (The Ohio State University)
• 2023: Occupational English Test (OET)
• 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
• 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
• 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

Memberships:

• American Society of Clinical Oncology (ASCO) - 2022
• Turkish Society of Medical Oncology - 2020

フォックス・ヴィオラ博士は、BKZゾーリンゲン血液腫瘍科・緩和医療科の主任医師です。同クリニックは、認定された集学的腫瘍センターです。フォックス博士は、ドイツおよびヨーロッパにおける腫瘍性疾患の薬物療法の第一人者であり、15年以上の臨床経験を有しています。

同博士は、ドイツ腫瘍学・血液腫瘍学会（GDHO）、ドイツ医師会、およびアメリカがん研究学会に所属しています。また、分子生物学の研究にも従事しており、その研究成果はがん治療および分子診断の発展に貢献しています。

主な専門領域は、化学療法、免疫療法、分子標的療法、および放射線療法です。フォックス博士は、革新的な治療法と患者への細やかな配慮で知られています。その取り組みにより、高い治癒率を達成し、同僚からの高い評価を得ています。

セヴェリン・イボラ医師は、Städtisches Klinikum Solingenの産婦人科における主任医師です。その担当領域は、産科、分娩室、新生児室、および婦人科に及びます。同科にはさらに、マヌエラ・ザイフェルト医師が主導するBergisches Breast Center Solingenの乳腺科クリニックも含まれています。

セヴェリン・イボラ医師はフランス出身です。リヨン大学で医学の学習を開始した後、フライブルクのアルベルト・ルートヴィヒ大学に転学し、2007年に医師免許を取得しました。2008年には分子腫瘍学の実験的研究により博士号を取得しています。2008年8月から2013年11月まで、フライブルク大学附属婦人科クリニックにて研修医として勤務し、産婦人科専門医試験に合格後、同クリニックで専門医としてキャリアを継続しました。2015年11月には、アーヘンのRWTH大学附属病院に上級医師として着任しました。

E・シュティケラー教授・医師が率いる産婦人科クリニックにおいて、イボラ医師は2017年から2019年にかけて産科部門を統括しました。2017年12月からは部門内の研修運営を担当し、2019年10月には管理上級医師および人事担当上級医師に就任し、ゾーリンゲンへの異動まで同職を務めました。

多数の論文発表および主要婦人科学会での講演を含む学術活動に加え、イボラ医師は医療専門分野をさらに深化させました。婦人科腫瘍学研究グループによる腫瘍診断・治療の認定資格を取得するとともに、子宮頸部病理学およびコルポスコピー（AGCPC）、泌尿器婦人科学および骨盤再建手術（AGUP）、ならびに婦人科医師職能団体（BVF）における追加資格を取得しています。

2019年には、「婦人科腫瘍学」および「特殊産科学・周産期医学」における追加専門資格を修了しました。ドイツ産婦人科学会、子宮頸部病理学およびコルポスコピー研究グループ、ならびにドイツ出生前・周産期医学会など、当該分野における主要なドイツ医学学術団体の積極的な会員として活動しています。

婦人科部門で提供する処置

• 子宮鏡検査、および子宮頸管拡張・子宮内膜掻爬術（D&C）（診断・治療目的）。
• 卵巣の異常または有症状病変の摘出（嚢腫など）、残存卵巣の温存を伴うもの。
• 卵巣摘出術（異常が認められる場合、または適応に応じた予防的目的による）。
• 子宮筋腫核出術（子宮温存を伴う子宮筋腫の摘出）。
• 子宮筋腫の保存的治療：薬物療法または放射線科専門医による塞栓術。
• 子宮全摘出術（子宮頸部の摘出を伴う場合および伴わない場合）。
• 子宮頸部、腟、外陰部における不明所見の診断および精査。
• 異形成の治療。
• 子宮内膜症の治療。
• 悪性腫瘍の治療（外陰部、腟、子宮頸部、子宮、卵巣）。
• 尿失禁および／または骨盤臓器脱の治療。

可能な限り、すべての処置は腹腔鏡またはダ・ヴィンチロボット支援システムを用いた低侵襲治療として提供しています。

Lee Ji Hyun医師は、乳腺・甲状腺外科医です。Lee Ji HyunはNaeun Hospitalにて乳腺・甲状腺外科部門を統括しています。専門領域：乳腺良性疾患、乳癌、腫瘍外科。その他の専門：甲状腺良性疾患、甲状腺癌、副甲状腺疾患。専門技術：マンモトーム処置、腋窩リンパ節手術、乳腺・甲状腺超音波検査。

学歴および研修歴：延世大学医科大学卒業。延世大学Severance病院にて一般外科インターンおよびレジデント研修修了。日本がん研究所附属病院にて短期臨床研修を修了。

主な職歴：Incheon Christian Hospital一般外科部長、Cheil Hospital一般外科専門医。Samsung Cheil Hospital乳腺センター長および外科部長。Cheil Hospital一般外科部長および診療副院長。CHA大学CHA江南メディカルセンター外科非常勤教授。Daejeong Hospital一般外科部長。

Education:

• Degree: Faculty of Medicine, Trakya University, 2009
• Medical Specialty: Internal Medicine, Bakırköy Dr. Sadi Konuk Training and Research Hospital, 2010-2014
• Specialist Doctor: Internal Medicine, Kanuni Sultan Süleyman Training and Research Hospital, 2014-2019
• Specialist Doctor: Internal Medicine, Turkish Hospital Internal Medicine Clinic, Qatar, 2019-2020
• Specialist Doctor: Internal Medicine, Istanbul Medipol University Hospital Mega Hospital Internal Medicine Department, 2020-2024
• Associate Professor Doctor: Internal Medicine, Istanbul Medipol University Medipol Acıbadem Regional Hospital, 2024-Present.

Roles in Projects:

Sub investigator (Assistant Researcher) in the SOUL Study: Cardiovascular Outcome Research of Semaglutide in Type 2 Diabetic Patients, approved by the Turkish Medicines and Medical Devices Agency on May 22, 2019.

Sub investigator (Assistant Researcher) in the international study “SCALE™ Insulin”: Efficacy and Safety of Liraglutide 3.0 mg in Overweight or Obese Patients with Type 2 Diabetes Treated with Basal Insulin (Study Code: NN8022-4272), conducted by Novo Nordisk A.Ş.

Subinvestigator (Assistant Researcher) in the international study NN5401-4266 StepByStep Intensification conducted by Novo Nordisk.

Assistant Researcher in the study "A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)" (2019-2020).

Assistant Researcher in the PIONEER 1 study: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.

ヴィクトル・アレクサンダー・クロル医師 — マルティヌス病院 消化器内科・内科・肥満治療センター長

ヴィクトル・アレクサンダー・クロル医師は、消化器内科および内科を統括する高度な専門医です。長年にわたる豊富な経験と深い専門知識を持つクロル医師は、卓越した専門家として広く認められており、患者一人ひとりに対して包括的な治療と個別化されたアプローチを提供しています。消化管疾患、代謝疾患、ならびに循環器疾患および呼吸器疾患の診断・治療において、最新の手法を積極的に活用しています。

クロル医師はまた、マルティヌス病院における認定肥満治療センターの責任者も務めており、同センターでは肥満に対する外科的および内視鏡的治療が提供されています。このセンターでは、肥満症（アディポシタス）の診断と治療に最先端の技術が導入されており、肥満外科手術（バリアトリック手術）、内視鏡的減量療法、さらには各種肥満病期の患者を対象とした専門的プログラムなどが実施されています。同センターは高い水準に基づいて認定を受けており、この重篤な疾患の治療において優れた実績を上げています。

クロル医師が率いる消化器内科では、胃・腸・肝臓・膵臓・胆嚢の疾患の診断および治療を行っています。内視鏡的処置、超音波検査をはじめとする幅広い最新の診断技術が活用されています。

内科部門は、循環器科、糖尿病科、感染症科、ならびに呼吸器疾患・腎疾患の治療を含む広範な疾患領域を対象としています。クロル医師とそのチームは、最先端の医療手法を用いた包括的な治療アプローチを提供しています。

高い専門性と患者一人ひとりへの真摯な姿勢により、クロル医師は同僚および患者から深い尊敬を集めています。

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Dr Tian Jian Qing is Director of Endocrinology and a Senior Expert in Endocrine & Metabolic Therapeutics. He has over 20 years of clinical experience. He previously worked at Xinjiang Military Command General Hospital and at Renji Hospital, Shanghai Jiao Tong University.

He has published over 20 SCI and Chinese core journal papers. He is chief editor of four monographs and co-editor of four others. He has produced more than 1,000 health education materials. His clinical focus includes endocrine and metabolic disorders, dysglycemia, dyslipidemia, and hypertension. He also treats weight, thyroid, and bone diseases, menopausal syndrome, PCOS, and gestational diabetes and thyroid disorders.

He holds Standing Council and Committee roles in the Fujian Cross-Strait Medicine & Health Exchange Association and the Fujian Primary Health Association. He also serves in the Xiamen Medical Association and the Xiamen Medical Doctor Association. He is Deputy Chair of the Diabetes Branch of the Xiamen Medical Association.

Education and Expertise

• 1989 BORNOVA ANATOLIAN HIGH SCHOOL
• UNDERGRADUATE DEGREE 1995 EGE UNIVERSITY/ FACULTY OF MEDICINE
• SPECIALIZATION IN MEDICINE 2001 DOKUZ EYLÜL UNIVERSITY/MEDICAL FACULTY INTERNAL MEDICINE DEPARTMENT
• MEDICAL SPECIALIST 2005 DOKUZ EYLÜL UNIVERSITY FACULTY OF MEDICINE ENDOCRINE AND METABOLISM DISEASES

Biography

Our doctor admits patients aged or older than 15.

Medical Education

School of Medicine, Ege University

Medical Residency

Department of Internal Medicine, School of Medicine, Dokuz Eylül University

Department of Endocrinology, School of Medicine, Dokuz Eylül University

Areas of Interest

Diabetes Mellitus

Thyroid Diseases

Pituitary Diseases

Hirsutism

Osteoporosis

Membership

Turkish Society of Endocrinology and Metabolism

Experience

• 2005-2009 Private Western Anatolia Central Hospital
• 2009-2011 Private Healing Hospital
• 2011-2016 Private Izmir Sifa University
• 2016-2023 Izmir Medical Point Hospital

Professional Memberships

• Turkish Medical Association
• Turkish Endocrinology and Metabolism Association

Education and Experience

• 1992 - 1998, Gaziantep University, Faculty of Medicine
• 2002 – 2015, Cumhuriyet University, Faculty of Medicine, Department of Internal Medicine
• 2015 – 2024, Bağcılar Medipol Mega University Hospital
• 2024 – Present, Medipol Acıbadem Hospital

Education

• 1986-1989, Bursa High School, Bursa, Turkey
• 1989-1995, Istanbul University, Istanbul School of Medicine, Turkey
• 1999-2003, (Residency) Kadir Has University, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey
• 2015, (Associate Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2021, (Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

Experience

• 1995-1999, Şişli Florence Nightingale Hospital, Istanbul, Cardiology Department
• 2003, Gayrettepe Florence Nightingale Hospital, Istanbul, Department of Radiation Oncology
• 2015, (Associate Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2021, (Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

Education

Ondokuz Mayıs University Faculty of Medicine (1991)

KTÜ Faculty of Medicine Farabi Hospital (Specialization.1998)

Istanbul University Çapa Faculty of Medicine (Laparoscopic Surgery Training, 2002)

Istanbul University Çapa Faculty of Medicine (Laparoscopic Antireflux Surgery Training, 2006)

Istanbul University Cerrahpaşa Faculty of Medicine (General Surgery Clinic Advance Laparoscopic Surgery, Laparoscopic Bariatric Surgery, Morbid Obesity and Oncological Cancer Surgery Training, 2010i)

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Education and Expertise

• 2023 BAKIRÇAY UNIVERSITY ÇİĞLİ TRAINING AND RESEARCH HOSPITAL (ASSOCIATE PROFESSOR)
• 2021 EGE UNIVERSITY FACULTY OF MEDICINE GASTROENTEROLOGY DEPARTMENT
• 2017 EGE UNIVERSITY INTERNAL MEDICINE DEPARTMENT
• 2010 EGE UNIVERSITY FACULTY OF MEDICINE

Diseases

• Liver Diseases
• Digestive System Diseases

Treatment Methods

• Endoscopy
• Endoscopic mucosal resection – EMR
• Endoscopic Obesity Treatment (Intragastric Botox, Intragastric Balloon)
• Endoscopic Polypectomy
• Endoscopic Retrograde Cholangio Pancreatography (ERCP)
• Liver Transplant
• Colonoscopy
• Peroral Cholangioscopy

Experience

• Diyarbakir 112 Emergency Health Services Chief Physician (2010-2011)
• Ege University Faculty of Medicine, Department of Internal Medicine (2012-2017)
• Ayvalik State Hospital (2017-2018)
• Ege University Faculty of Medicine, Department of Gastroenterology (2018-2021)
• Burdur State Hospital (2021-2022)
• Bakırçay University Çiğli Training and Research Hospital (2022-2024)

Professional Memberships

• 1.Turkish Gastroenterology Association (ERCP working group)
• 2. Turkish Liver Research Association
• 3. Turkish Medical Association

Dr. Zuhal Cakmak Peksen is a Family Medicine Specialist since 2017. She earned her MD from Çukurova University in 2010. She completed specialty training at Yüzüncü Yıl University between 2013 and 2017. She is currently studying for a bachelor’s degree in Health Management at Anadolu University (2024–present).

She has 15 years of clinical practice (2010–2025) across 8 institutions. Her experience includes research in Family Medicine (2013–2017) and work at several Family Health Centers. Since 2020, she has served at TOKİ Avrupa Family Health Center in Gaziosmanpaşa, Istanbul.